Targeted Fetal Hemoglobin Induction for Treatment of Beta Hemoglobinopathies
- 1 April 2014
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 28 (2) , 233-248
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin inductionNature Medicine, 2013
- A Functional Element Necessary for Fetal Hemoglobin SilencingNew England Journal of Medicine, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- KLF1 regulates BCL11A expression and γ- to β-globin gene switchingNature Genetics, 2010
- Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobinNature Genetics, 2010
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseProceedings of the National Academy of Sciences, 2010
- Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6Genes & Development, 2010
- Control of fetal hemoglobin: new insights emerging from genomics and clinical implicationsHuman Molecular Genetics, 2009
- DNA polymorphisms at the BCL11A , HBS1L-MYB , and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell diseaseProceedings of the National Academy of Sciences, 2008
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008